NCT04428424View on ClinicalTrials.gov

Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients

CompletedOBSERVATIONAL
Enrollment

1,493

Participants

Timeline

Start Date

July 5, 2020

Primary Completion Date

August 30, 2020

Study Completion Date

August 30, 2020

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Enbrel

As provided in real world practice

Trial Locations (1)

Unknown

Pfizer, Baghdad

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04428424 - Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients | Biotech Hunter | Biotech Hunter